News|Articles|July 16, 2021

Tevogen Bio Partners with Yale in Regulatory Sciences Program Expansion

The Yale School of Public Health’s regulatory sciences program expansion builds on the current regulatory affairs track program, which focuses on the administrative, policy, and legal aspects of product regulation.

Tevogen Bio announced in a July 14, 2021 press release its support of the Yale School of Public Health’s regulatory sciences program expansion, providing students with professional training. This expanded program builds on the current regulatory affairs track in the Yale School of Public Health’s Master of Public Health program, which focuses on the administrative, policy, and legal aspects of product regulation.

Regulatory sciences on the other hand, focuses on the development of new tools, standards, and approaches to assess the safety, efficacy, quality, and performance of products made by pharmaceutical, biologic, and medical device organizations, in addition to other industries.

“Stakeholders are searching for talented and emerging leaders in regulatory science, but current educational programs are scarce,” said Sten H. Vermund, Dean of the Yale School of Public Health, in a press release. “With Tevogen Bio’s support, we have an opportunity to reimagine our program and to grow it into one that matriculates students who ultimately become national and international leaders in the field.”

Source: BusinessWire, Tevogen


Related to this article

Pharma Logistician Using IoT Based On Blockchain | Image Credit: ©leowolfert -stock.adobe.com
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
AAPS PharmSci 360: CMC Strategies, Part 3
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.